Also known as: ABT-263
Drug Information: Protein and enzyme inhibitors are novel new therapies for follicular lymphoma which remain experimental, but are highly promising. One such drug is navitoclax.
Trial Information: A Phase II trial of navitoclax is ongoing as of 2010, and includes sites in Canada.
In an American Phase I trial initiated in 2006, most of the 55 patients enrolled suffered from side effects like anemia, infection, low blood cell counts, diarrhea, nausea, and fatigue. The patients had varying types of lymphomas, and there was a 22% overall response rate (median progression-free survival, 15 months). Another Phase I trial combined navitoclax with rituximab as first-line treatment, resulting in a 67% overall response rate, including 4 complete remissions and 1 partial response in 11 follicular lymphoma subjects (45%).
Published Studies
Brad Kahl et al. "Navitoclax (ABT-263) Plus Rituximab." ASH Convention, 2010.
Wyndham H. Wilson et al. "Navitoclax, A Targeted High-Affinity of BCL-2." Lancet Oncology (2010).
No comments:
Post a Comment